Simvastatin ameliorates altered mechanotransduction in uterine leiomyoma cells.

This study demonstrated that simvastatin targets altered β1 integrin-mediated mechanotransduction pathway in uterine leiomyoma cells. Treatment of leiomyoma cells with simvastatin reduced β1 integrin expression and FAK phosphorylation. In addition, we observed that simvastatin attenuated RhoA activation and collagen gel contraction. Furthermore, this drug inhibits the downstream targets of β1 integrin signaling, potentially correcting the dysregulated mechanical signaling in leiomyoma. Therefore, this suggests that simvastatin may inhibit uterine leiomyoma growth, at least in part, by ameliorating the altered mechanotransduction process. Mechanotransduction process starts when signals from ECM components (such as collagen) activate integrins (transmembrane receptors composed of α and β heterodimers) which transmits signals from outside to inside cells. 5 , 21 Upon activation, integrins activate two related downstream pathways; a cytoskeleton mechanical pathway and a biochemical signaling one. In the cytoskeleton mechanical pathway, integrins activation leads to polymerization and organization of G-actin molecules to form F-actin fibers to which integrins are connected via linker proteins. This pathway is involved in cellular processes such as contractility and cytoskeletal rearrangement. 22 Integrins are conceivably the target of first choice to modulate mechanosensing. In fact, inhibition of integrin was associated with a significant reduction of uterine leiomyoma cells proliferation and cytoskeletal rearrangement. 10 In addition, simvastatin was shown to downregulate β1 integrin, FAK phosphorylation and cellular proliferation in other tumor types. 23 In the present study, we found that simvastatin significantly reduces the expression levels of β1 integrin in leiomyoma cells. In the biochemical signaling pathway, integrin activation and the formation of the focal adhesion complex triggers autophosphorylation of FAK which binds to the Src-homology 2 (SH2) domain of Src which further phosphorylates FAK and creates more binding sites for Src. 24 It shows that simvastatin dose-dependently reduces phosphorylation of FAK in leiomyoma cells compared to control. Cell-ECM adhesions are mainly accomplished via integrins. At the adhesion site, integrin bind their ECM ligands and initiates the intracellular recruitment. 25 Furthermore, interruption of ECM-β1 integrin signaling have remarkable inhibitory effects on leiomyoma cells progression. 9 Phosphorylated FAK leads to activation of AKAP13 5 , 26 and other intermediate cytoplasmic kinases that mediate different downstream signaling pathways, including Erk1/2, p38 MAPK and c-Jun N-terminal kinase (JNK), and PI3K. 27 Recently, AKAP13 was reported to augment progesterone-mediated transcriptional response in leiomyoma cells 11 , suggesting AKAP13 as a leiomyoma therapeutic target. In fact, ulipristal acetate and omega-3-fatty acids downregulate AKAP13 expression in uterine leiomyoma. 11 , 28 In this study, we also found that simvastatin decreases AKAP13 expression in leiomyoma cells. AKAP13 contains RhoA GTPase-specific guanine exchange factor (GEF) which activates Rho and its downstream signaling. 6 In turn, activated RhoA contributes to the production of ECM, alters the viscoelastic properties of tissue, and contributes to increased ECM stiffness, all are key features of leiomyomas. 8 The link between β1 integrin and active RhoA in the mechanotransduction process was further demonstrated by the observation that inhibition of β1 integrin leads to a decrease in active RhoA. 10 We found that simvastatin treatment dose-dependently decreases RhoA activation in uterine leiomyoma cells. ROCK is one of the main effectors of RhoA, which regulates cytoskeleton and cell polarity. 29 Fukushima et al. reported that inhibition of the Rho/ ROCK pathway is associated with suppression of collagen production and augmentation of collagenase activity in hepatic stellate cells. 30 Fasudil, an inhibitor of ROCK, was reported to decrease expression of ECM proteins fibronectin, procollagen 1A, and versican in leiomyoma cell cultures and relax the contraction of 3D collagen gels. 17 In the present study, we found that treatment of leiomyoma cells with simvastatin dose-dependently reduced ROCK1 expression and repressed 3D collagen gel contraction compared to the control. MLCK is a Ca 2+ /calmodulin-dependent serine/threonine kinase 31 , which is involved in cytoskeleton organization, cell contraction, cytokinesis, and aggregation. 32 This serine/threonine kinase phosphorylates the regulatory light chain of myosin that allows myosin to bind to actin filaments. 33 A significant role of stiff substrate, integrin binding, and MLCK activation in cell spreading and migration have been demonstrated. 34 It was shown that MLCK can regulate myosin II-mediated periodic lamellipodial contraction. 34 The inhibition of MLCK has been associated with the reduction of ventilator-induced lung injury 35 , and NADPH oxidase-induced oxidative injury in the brain of rats. 36 Treatment of leiomyoma cells with simvastatin also showed reduced levels of MLCK at dose-dependently, suggesting the potential role of simvastatin as a possible MLCK inhibitor. We have previously shown that simvastatin treatment inhibits the phosphorylation of ERK1/2 in leiomyoma cells. 12 , 13 Here, we found reduced levels of cyclin D1 after simvastatin that further confirms the inhibitory effect of simvastatin on leiomyoma cell growth. Moreover, collagens serve as a central structural component of ECM and are involved in proliferation, wound healing and fibrosis. 37 In our previous study, we found that simvastatin reduces collagen I expression in leiomyoma cells. 14 The present study confirms this inhibitory effect and further elucidate on the pathway. Interestingly, some results showed a U-shaped dose-response curve. In Fig. 4A / 4B , the FAK mRNA U-shape is mirrored by a similar pattern in total FAK protein levels ( Fig. 4C / 4D ). We believe this may be due to specific dose-dependent inhibition of regulatory or feedback loops in the signal pathways. For example, at a very low dose, the drug can hit certain target sites. However, at higher concentrations, the drug may hit additional target sites in such a way to change the overall effect. Similar U-shaped responses have been reported in anti-tumor treatments. 38 The U-shaped response noted in AKAP13, ROCK1 and MLCK mRNA levels ( Fig 8A , B , C ) was not paralleled by protein levels ( Fig 9A , B , C ), possibly due to dose-dependent mRNA post-transcriptional modifications. This study has several clinical and research implication. It provides a novel mechanism to explain the clinically relevant anti-leiomyoma properties of simvastatin seen in cellular and animal experiments. 12 , 13 The stiffness and disordered mechanical homeostasis in leiomyoma are major contributors to leiomyoma development and discovering that simvastatin ameliorates them can open the door for further studies. We are currently performing a project to measure the effects of simvastatin on the stiffness of uterine leiomyoma tissue using an explant system. Simvastatin has been in use for more than 20 years as a treatment of high cholesterol, cardiovascular disease and other conditions. In a nested case-control study using insurance databases, statin users had a lower leiomyoma risk and less symptoms compared to nonusers. 39 In addition to providing a mechanism, the findings of the current study validate the case for the currently ongoing phase II clinical of simvastatin in uterine leiomyoma. As an anti-leiomyoma treatment, simvastatin could have several advantages. Its safety profile and pharmacokinetics are well-known and can be used for extended periods of time. It is a non-hormonal option and therefore can be used in many cases where hormonal options such as oral contraceptives are contraindicated. Many patients with uterine fibroids have hyperlipidemia and other conditions where simvastatin can have more than one beneficial effect. In addition, it is inexpensive and is already available in a generic form. Needless to say, the consideration of simvastatin as a therapeutic option for uterine leiomyoma must be only after clinical trials confirm its efficacy and safety. It is difficult to ignore the striking similarities of the effects of simvastatin on ECM in uterine leiomyomas and atherosclerotic patches. There is also evidence linking the development of uterine leiomyoma with several cardiometabolic risk factors. 40 In fact, the atherogenic hypothesis suggests that atherosclerosis and uterine leiomyoma may share several characteristics. 40 Similarly, there evidence that statins in general possess several beneficial effects on uterine leiomyoma, endometriosis and other gynecologic conditions. 41 , 42 The association of benign gynecologic conditions such as leiomyoma and endometriosis with cardiometabolic risk factors seems important and deserve further clinical and mechanistic investigation. This is the first report of the beneficial effects of simvastatin on altered mechanotransduction in uterine leiomyoma. In this study, we used both primary and immortalized human leiomyoma (HuLM) cells. Primary cells were isolated from fibroids after surgery. HuLM cells were previously isolated from fibroid tissue and immortalized by retroviral vector carrying human telomerase reverse transcriptase. Each cell types has its own advantages and disadvantages. The behavior of primary cells is very close to in vivo biology. However, they can be used for only few passages before they start to show morphologic changes. On the other hand, immortalized cells can be maintained for several passages without changes. However, the immortalization process may have introduced some differences. Overall, immortalized cells present an important tool in cellular and molecular biology research. We have decided to do most experiments in both cells types to capitalize on advantages both cell types. We clearly stated which cell type was used in each experiment. The study may have been impacted by some limitations. Experiments were only performed in vitro. In vivo data (animal models and human tissue) can be valuable to verify in vitro results. We plan xenograft animal experiments. In addition, our ongoing clinical trial ( clinicaltrials.gov number NCT03400826 ) will provide tissues for in vivo studies. Our experiments were limited to simvastatin and other statins were not examined. This decision was based on our previous works using simvastatin. We also have not investigated the exact mechanism by which simvastatin lowers the expression level of β1 integrin and other proteins, which we plan to undertake in future work. In summary, our study shows that simvastatin ameliorates several dysregulated steps of the mechanical signaling cascade ( Fig. 11 ). Future studies can examine if these findings will be replicated in leiomyoma tissue from the ongoing phase II clinical trial patients. Furthermore, this clinical trial can show if these molecular and cellular changes are associated with clinical improvement in symptoms, tumors size, or both.

Leiomyoma cells overexpress integrins, a phenomenon believed to contribute to altered mechanotransduction and tumor development. 9 To explore the effect of simvastatin on β1 integrin expression, we treated primary and HuLM cells for 48 h with different simvastatin concentrations (0.001, 0.01, 0.1, 1μM or control). We found that simvastatin treatment reduced β1 integrin mRNA transcripts to 22-39% in primary and 17-40% in HuLM cells of controls, though there was some variability ( Fig. 2A and 2B ). Consistent with the reduced mRNA expression, simvastatin reduced β1 integrin protein expression by 29-38% in primary leiomyoma cells and 30-44% in HuLM cells, compared to untreated cells ( Fig. 2C and 2D ). Similar to the mRNA and protein expression, we examined the expression of β1 integrin and its co-localization with F-actin by immunofluorescence both in primary and HuLM cells. As shown in Fig.3 , β1 integrin (green fluorescence) was present in high levels in primary ( Fig. 3A ) and HuLM ( Fig. 3B ) cells, while simvastatin clearly reduced expression in a dose-dependent manner. Of note, while the effect size in some of the results was large, e.g. about 30% reduction of β1 integrin protein expression at 0.01μM simvastatin in primary cells, in other situations the effect size was small. We should exercise caution when clinically interpreting results with a small effect size, even if statistically significant. This applies here and in other sections. In leiomyoma cells, FAK phosphorylation was found to be upregulated compared to myometrium and contribute to activation of β1 integrin downstream signaling. 9 We found that simvastatin treatment reduced FAK mRNA transcripts in primary and HuLM cells displaying a “U” shaped curve, with maximal reductions observed at 0.01 and 0.1μM ( Fig. 4A and 4B ). Next, we evaluated the effect of simvastatin on FAK phosphorylation using western blotting. Primary and HuLM cells demonstrated a significant reduction of pFAK to total FAK ratio, to 24-32% and 26-60% normalized to controls ( Fig. 4C and 4D ). While simvastatin reduced pFAK, it seemed to increase total FAK protein expression at 1 μM, similar to mRNA findings. Similar to β1 integrin expression, we examined FAK phosphorylation after simvastatin treatment in primary and HuLM cells by using immunofluorescent staining. We found that spotty membranous phosphorylated FAK (pFAK) was greatly reduced in primary ( Fig. 5A ) and HuLM ( Fig. 5B ) cells treated with simvastatin compared to control. There is evidence that mechanical stress from disordered ECM is associated with overactivation of RhoA in uterine leiomyoma cells. 8 To characterize the effect of simvastatin on RhoA activation, we used RhoA pull down assay after treating HuLM cells for 48 h. As shown in Fig. 6 , simvastatin decreased active-to-total RhoA ratio except at lower concentrations. Cell-matrix interaction is achieved largely via integrins which physically link cellular cytoskeleton to ECM proteins. 18 Since we observed that simvastatin reduced integrin expression, we investigated the effect of simvastatin on cellular response to the ECM in a gel contraction assay. RhoA/ROCK signal transduction, a vital mediator of contractility 19 , was found to be overactive in leiomyoma cells. 8 , 10 Having found that simvastatin reduced levels of active RhoA, we tested the effect of simvastatin in a collagen gel contraction assay. HuLM cells were cultured in 3D using rat-tail collagen for 2 weeks. Thereafter, cells were treated with different concentrations of simvastatin or control for 96 h. Then, gel contraction was examined by capturing the images and comparing the gel surface area of each treated well to control. As shown in Fig.7 , different simvastatin doses inhibited collagen gel contraction. Moreover, the higher concentrations of simvastatin induced maximum gel relaxation, with the gel diameter similar to gel without cells. Gel diameter is a convenient technique to quantity cell-ECM contraction force within the collagen matrix. To test whether the reductions in pFAK and RhoA affected proteins involved in mechanical signaling downstream of β1 integrin, we measured levels of mRNA and proteins of factors downstream of β1 integrin activation in HuLM cells treated with simvastatin for 48 h. The mRNA level of AKAP13 demonstrated a significant reduction to >50% of controls ( Fig. 8A ). Similarly, the mRNA levels of ROCK1 and MLCK were significantly decreased to a range of 64% ( Fig. 8B ), and 49% ( Fig. 8C ) of control. Additionally, mRNA level of cyclin D1 was significantly downregulated at all simvastatin concentrations by 80% of control ( Fig. 8D ). Regarding protein expressions, at 1μM simvastatin concentration, the expression of AKAP13 was suppressed by 38% ( Fig. 9A ) whereas the expression of ROCK1 and MLCK were decreased by 30% ( Fig. 9B ) and 35% ( Fig. 9C ) of control. In addition, the expression of cyclin D1 decreased by 37% at 1μM concentrations ( Fig. 9D ). Type I collagen is known to be overexpressed in leiomyoma and have a significant impact on integrins activation. 10 , 20 To examine the effect of simvastatin on type I collagen expression, we treated HuLM cells for 48 h with different simvastatin concentrations and measured mRNA and protein expression. As shown in Fig. 10A , simvastatin treatment was associated with a significant reduction in mRNA transcripts compared to control. In addition, the protein expression of type I collagen was suppressed to 27-60% compared to control ( Fig. 10B ).

Primary leiomyoma cells were isolated from five patients who underwent hysterectomy at the Department of Gynecology and Obstetrics at the Johns Hopkins University Hospital. Institutional review board (IRB) at the Johns Hopkins University reviewed and approved the study and informed consents were obtained from patients. Tissues were brought to the laboratory immediately after surgery and washed several times with a Hanks' Balanced Salt Solution (HBSS, Thermo Fisher Scientific, Waltham, Massachusetts) without calcium or magnesium. Leiomyoma tissue was manually cut into small pieces (1-2 mm 3 ). We then incubated tissues in sterile HBSS (without phenol, calcium, or magnesium) with collagenase (Worthington, Lakewood, New Jersey), deoxyribonuclease (DNase, Sigma-Aldrich), antibiotic-antimycotic mixture (Thermo Fisher Scientific), and HEPES buffer solution (Thermo Fisher Scientific) at 37°C on a shaker for 4-8 h. The digest was filtered through a 100-μm filter and cultured in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM)/F-12 (Thermo Fisher Scientific) medium supplemented with HEPES, L-glutamine, 10 % FBS, and 1% antibiotic-antimycotic. Immortalized human leiomyoma (HuLM) cells were cultured and maintained in smooth muscle cell growth medium (SmGM, Lonza, Walkersville, Maryland) which includes smooth muscle basal medium (SmBM), 5% fetal bovine serum (FBS), 0.1% insulin, 0.2% recombinant human fibroblast growth factor B, 0.1% gentamicin sulfate and amphotericin B mixture, and 0.1% human epidermal growth factor. Cells were incubated at 37 °C in a humidified atmosphere (95% air, 5% CO 2 ) and split at 70-80% confluence. We purchased simvastatin from Cayman Chemicals (Ann Arbor, MI), prepared stock solution (10 mM) in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO), and kept it at −20°C until use. The final concentration of DMSO in culture medium was less than 0.1% v/v. Primary and HuLM cells were plated in a 6-well plate at a concentration of 1.2 x 10 5 cells/well and maintained with complete DMEM/F-12 or SmGM media, respectively, until 60-70% confluence. After overnight serum starvation, cells were treated with complete medium containing 0.001, 0.01, 0.1 and 1μM simvastatin for 48 h. We chose these concentrations based on clinical relevance and previous publications. 13 , 14 Control cells were exposed to vehicle (DMSO). Cells were harvested and pellets obtained by centrifugation at 1500 rpm for 10 minutes. The total RNA content of the cells was measured using an RNeasy Mini Kit (Qiagen, Gaithersburg, MD) as per manufacturer’s instructions. RNA concentration and purity were checked by using the NanoVue Plus (Biochrom US, Holliston, MA). Reverse transcription was performed using the iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) in a Bio-Rad Thermocycler according to the manufacturer’s instructions. The 100 ng/μL of total RNA from each sample was reverse-transcribed in 20 μl reaction volume to complementary DNA (cDNA). The qRT-PCR was performed using the LightCycler® 96 System (Roche Diagnostics, Mannheim, Germany) using FastStart Essential DNA green Master (Roche Diagnostics) according to the manufacturer's protocol. An equal amount of cDNA of each sample was added to the master mix containing appropriate primer sets in a 10 μl reaction volume. All experiments were performed in duplicate and repeated three times. RPLP0 was amplified under the same qRT-PCR conditions for normalizing quantitative data. Forward and reverse primer sequences (IDT, Coralville, Iowa) used for determining the messenger RNA (mRNA) expression of several genes, including β1 integrin, FAK, AKAP13, ROCK1 (Rho associated protein kinase 1), MLCK (myosin light chain kinase), cyclin D1, and type I collagen ( Supplementary table 1 ). The relative mRNA expression was calculated using the ΔΔCT method and is presented as fold increase relative to control levels expressed as 1.00. Primary and HuLM cells were cultured in 100 mm dish (5 x 10 5 cells/dish) with complete DMEM/F-12 or SmGM media, respectively, until they reach 60-70% confluence. After overnight serum starvation, cells were treated with complete medium containing 0.001, 0.01, 0.1 and 1μM simvastatin or DMSO (control) for 48 h. Cells were lysed in radio immunoprecipitation assay buffer (RIPA, Sigma-Aldrich) containing protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Protein concentrations were quantified using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). For western blotting, 30-40 μg of protein lysates were resolved in 4-12% Bis-Tris Protein Gradient Gels (Thermo Fisher Scientific) for electrophoresis and then transferred onto a nitrocellulose membrane (Thermo Fisher Scientific). The membrane was blocked with 5% non-fat-milk with Tris buffered saline with 0.1 % Tween 20 (TBST, Thermo Fisher Scientific) for 1 h at room temperature. Membrane were incubated with specific primary antibodies: anti-collagen I (Thermo Fisher Scientific, #PA5-29569), anti-β1 integrin (Cell Signaling Technology (CST), #4706), anti-FAK (CST, #3285S), anti-phospho-FAK (CST, #8556), anti-ROCK1 (CST, #4035), anti-MLCK (Thermo Fisher Scientific, #PA5-46298), anti-cyclin D1 (CST, #2922) overnight at 4° C. For preparing anti-AKAP13, rabbit primary antisera was focused counter to AKAP13 and a peptide corresponding to the AKAP13 protein (CREKEKDKIKEKEKDS KEKEKDKKTLNGHTF) was generated polyclonal antiserum 6969 using standard techniques. BRX binding was confirmed by enzyme-linked immunosorbent assay (Covance Laboratories, Sterling, VA). 16 Membrane were incubated with appropriate horseradish Peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare) for 1 h at room temperature. Immunolabeled proteins were identified by using a SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific) and specific protein bands were visualized using Azure Imager c300 (Azure Biosystems, Dublin, California). The band intensity was quantified using NIH Image J software and normalized against corresponding anti-β-actin antibody (CST, #4970); normalized values were used to create final graphs. Primary and HuLM cells were cultured on an 8-well chamber slide (3x10 3 cells/well). When cells reached 60% confluence, they were serum-starved overnight then treated with 0.001, 0.01, 0.1 and 1μM simvastatin or DMSO (control) for 48 h. Cells were fixed in a 4% formaldehyde solution for 15 minutes at room temperature. After washing three times in 1x PBS for 5 min each, cells were blocked for 1 h using blocking solution with 1x PBS, 5% normal goat serum (CST) and 0.3% Triton X-100 (Sigma-Aldrich) at room temperature. Primary antibodies, anti-pFAK (Thermo Fisher Scientific, #700013) and anti-β1 integrin (Invitrogen, #MA5-13658), and Alexa 647 phalloidin (staining of F-actin, CST) were diluted with antibody dilution buffer containing 1x PBS, 1% BSA (Sigma-Aldrich) and 0.3% Triton X-100 and cells were incubated overnight at 4°C in a moist chamber. After three gentle rinses with 1x PBS, the slide was incubated with anti-mouse Alexa 546 (Invitrogen, #A11030) and anti-rabbit Alexa 488 (Invitrogen, #A11034) conjugated secondary antibody (1 h at room temperature in the dark) for visualizing the pFAK and β1 integrin expression. After the last three rinses, the slide was fixed with Prolong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) overnight at room temperature. The cells were examined under a confocal microscope (Leica SP8 microsystem, Wetzlar, Germany). The exposure time is 1.9 microseconds per pixel. Each image was 4 megapixels, so the total duration was 7.6 seconds of scanning. The exposure time was similar for each collection. All images were captured with a 20X magnification. Fluorescence integrated density was quantified using NIH Image J software and is presented as fold change relative to control levels expressed as 1.00. Activated RhoA was measured using a commercially available Rho pull-down activation assay kit (Cytoskeleton Inc., Denver, CO) according to the manufacturer's protocol. The assay principle is that the Rho binding domain (RBD) of the Rhotekin GST-fusion protein binds active (GTP-bound) but not inactive (GPD-bound) Rho. In brief, HuLM cells were cultured and maintained in 100 mm dishes (5x10 5 cells/dish), serum-starved overnight, then treated with 0.001, 0.01, 0.1, 1 and 10μM simvastatin or DMSO (control) for 48 h. Cells were harvested on ice in lysis buffer with protease inhibitor cocktail. The active RhoA was pulled down using GST-Rhotekin-RBD protein beads after 1 h incubation at 4°C followed by washing the beads with washing buffer. The precipitated active RhoA was detected by western blotting using specific anti-RhoA monoclonal antibody and the band intensity was quantified as a ratio compared to total RhoA protein expressed in the same samples using NIH Image J software. The gel contraction assay was performed as previously described. 17 The principle is that cells are grown in a three-dimensional (3D) collagen gel matrix, which provides a physiological environment for the cells to grow. As cells interact with ECM collagen via integrins, the cell-ECM complex starts to contract, and the gel gets smaller over time. The more the contraction, the smaller the diameter of the gel. In brief, we prepared a total of 5 ml of rat tail collagen I and HuLM cell suspension by adding 2.5 ml of 6 mg/ml rat tail collagen-I (EMD Millipore), 1.5 ml complete SmGM medium, 0.5 ml of 5X PBS, 0.07 ml of 0.1M NaOH, and 0.43 ml medium containing 1x10 6 cell suspended. We then poured 0.5 ml of the suspension in each well in a 24-well plate (each will have about 1x10 5 cells). The plate was then incubated at 37°C for 30 minutes for the collagen to polymerize. Then, we added 0.5 ml SmGM and were kept in the incubator until the cells are 50-60% confluent (usually takes around 2 weeks). The medium is changed every 48-72 hours. The 3D HuLM gels were treated with 0.001, 0.01, 0.1, 1μM simvastatin or DMSO (control) for 96 h. Then, gels were moved from 24-well plate to 12-well plate, photographs taken and the gel surface area analyzed by NIH Image J software. All experiments were repeated three separate times and the data were expressed as mean ± standard error of the mean (SEM). Data were compared to control using an unpaired two-tailed Student t test using Prism 5 software (GraphPad Software, Inc., La Jolla, CA). Statistical significance was considered when p value was < 0.05.

Mechanotransduction is a dynamic process whereby cells respond to mechanical cues from the surrounding environment via cell membrane sensors and transform these mechanical signals into a series of cytoskeletal and intracellular biochemical signals. In turn, these cellular responses modulate several processes including the production of extracellular matrix (ECM) components. Thus, the mechanotransduction process is bidirectional (outside-in and inside-out) where both cells and the surrounding ECM affect each other to maintain homeostasis. 1 Uterine leiomyomas, the most common tumors of the female genital tract, are believed to originate from uterine smooth muscle cells. 2 - 4 A dysregulated ECM is a key feature of uterine leiomyomas. 5 Studies by our group 6 and others 7 indicate that altered mechanical signaling and homeostasis play a significant role in uterine leiomyoma development and growth. Uterine leiomyoma demonstrate increased mechanical stress, high ECM density and stiffness 6 , and altered response to mechanical cues. 8 Integrins are transmembrane receptors that play a key role in mechanosensing and mechanotransduction. Aberrations of integrins and integrin-mediated mechanotransduction appear to be major contributors to uterine leiomyoma pathobiology. 5 Leiomyoma cells overexpress β1 integrin 9 , 10 which leads to overphosphorylation of focal adhesion kinase (FAK) compared to matched normal myometrial cells. 10 Furthermore, A-kinase anchor protein 13 (AKAP13) is highly expressed in leiomyoma 11 and contributes to altered mechanotransduction by activating RhoA (ras homolog family member A) 6 , 8 ( Figure 1 ). Thus, considerable evidence indicates that fibroids do not respond properly to mechanical cues and suggested that restoration of normal mechanical signaling might be beneficial for leiomyoma treatment. Simvastatin is an inhibitor of the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase enzyme, the rate-limiting step in cholesterol biosynthesis. We previously demonstrated that simvastatin induces apoptosis, inhibits proliferation and suppresses tumor growth in leiomyoma cell culture and animal model. 12 , 13 In addition, it inhibits the expression of key ECM proteins, including types I and III collagen, fibronectin, versican, and brevican in leiomyoma cells. 14 Importantly, simvastatin has been shown to modulate mechanical signaling pathways. For example, simvastatin improves RhoA-mediated cellular response to increased matrix stiffness 15 which may prevent atherosclerosis instigated by age-related arterial stiffening. 15 Therefore, herein we explored the ability of simvastatin to ameliorate the perturbed mechanotransduction in uterine leiomyoma cells.